Curevac announces financial results for the fourth quarter and full-year 2022 and provides business update

In 2022, ongoing business transformation driven by covid-19 and flu clinical develop­ments in collaboration with gsk and successful broadening of oncology footprint early 2023, strong validation of curevac's proprietary mrna technology platform from positive preliminary phase 1 data in covid-19 and flu in collaboration with gsk monovalent modified covid-19 candidate cv0501 demonstrated efficient booster activity and good tolerability across now available dose range of 3 to 200Μg monovalent modified flu candidate flu-sv-mrna showed immunogenicity in line with licensed comparator at lowest dose of 2Μg; strong performance in older adults modified mrna technology selected as preferred technology; on track with new clinical studies in flu and covid-19 in q2 and later in 2023, with updated candidates on track with first proof-of-principle study in q2 2023 for clinical validation of second-generation mrna backbone in oncology progressing proprietary lnp development programs for optimized and targeted mrna delivery in prophylactic vaccines as well as cancer vaccines cash and cash equivalents position of €495.8 million as of december 31, 2022 $250 million in gross proceeds raised with issuance of 27,027,028 common shares in february 2023 extend cash reach to mid-2025 tÜbingen, germany and boston, ma / accesswire / april 25, 2023 / curevac n.v. (nasdaq:cvac) ("curevac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mrna"), today announced financial results for the fourth quarter and full-year 2022 and provided a business update.
CVAC Ratings Summary
CVAC Quant Ranking